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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYCardiomyocytes derived fromhuman embryonic stemcells (hESC-CMs) can improve the contractility of injuredhearts.Wehypothesized
thatmesodermal cardiovascular progenitors (hESC-CVPs), capable of generating vascular cells in addition to cardiomyocytes, would pro-
vide superior repair by contributing to multiple components of myocardium. We performed a head-to-head comparison of hESC-CMs
and hESC-CVPs and compared these with the most commonly used clinical cell type, human bone marrow mononuclear cells (hBM-
MNCs). In a nude rat model of myocardial infarction, hESC-CMs and hESC-CVPs generated comparable grafts. Both similarly improved
systolic function and ventricular dilation. Furthermore, only rare human vessels formed from hESC-CVPs. hBM-MNCs attenuated
ventricular dilation and enhanced host vascularization without engrafting long-term or improving contractility. Thus, hESC-CMs and
CVPs show similar efficacy for cardiac repair, and both aremore efficient thanhBM-MNCs. However, hESC-CVPs donot form larger grafts
or more significant numbers of human vessels in the infarcted heart.INTRODUCTION
Cell-based cardiac repair is an active research area in both
preclinical settings and in clinical trials. Because they are
easily accessible, have a favorable safety profile, and have
shown efficacy in preclinical studies, autologous bone
marrow mononuclear cells (hBM-MNCs) have been the
most frequent cell source used in clinical trials. However,
these clinical trials have shown discrepant results with
some studies demonstrating improved cardiac function
and clinical symptoms, whereas others have demonstrated
no such improvements (Chong, 2012). In addition, the
mechanism of action for hBM-MNC-induced cardiac effi-
cacy remains elusive. It is now accepted that transplanted
hBM-MNCs cannot create sufficient amounts of new car-
diac muscle for significant contractile force generation. A
more likely hypothesis is that their beneficial effect is
related to paracrine actions and induction of neoangiogen-
esis (Dai et al., 2013; Hansson et al., 2009; Kocher et al.,
2001; van der Bogt et al., 2008).
Recently, the beneficial effect of cardiomyocytes derived
from human embryonic stem cells (hESC-CMs) has been
demonstrated in various preclinical models of cardiacStem Cell Rinjury (Caspi et al., 2007; Chong et al., 2014; Laflamme
et al., 2007; Leor et al., 2007; Shiba et al., 2012; van Laake
et al., 2008). These studies show that hESC-CMs can
engraft and remuscularize the myocardium and preserve
the contractile function of the heart when injected shortly
after myocardial infarction. Furthermore recent studies
have demonstrated that hESC-CM grafts in the injured
hearts of guinea pigs and macaques form electromechan-
ical junctions with host cardiomyocytes and contract syn-
chronously with the host heart (Chong et al., 2014; Shiba
et al., 2012). However, while hESC-CM treatment can
halt the deterioration of cardiac function, they have failed
to improve already diminished cardiac function (Fernandes
et al., 2010), perhaps because the grafts have only repopu-
lated a small amount of the infarct. Thus, there is clearly
room for improvement.
Yang et al. (2008) described a novel population of human
tripotent cardiovascular progenitor cells that can be
derived from hESCs (hESC-CVPs). This population, identi-
fied on the basis of their KDR (VEGFR2)/PDGFRa expres-
sion, represents a promising source for heart repair, as these
cardiovascular progenitors have a restricted capacity to
differentiate into cardiomyocytes, smooth muscle cells,eports j Vol. 5 j 753–762 j November 10, 2015 j ª2015 The Authors 753
and vascular endothelium. This specific cell population
could, in principle, not only remuscularize the damaged
myocardium improving its contractility, but also promote
the revascularization of the injured area.
Thus, different cellular sources for cardiac repair remain
of considerable interest to the field. However, there is a
lack of studies directly comparing different cell types in
the same animal model. In the present study, we aimed
to determine the fate of three promising cellular sources
for cardiac repair—hBM-MNCs, hESC-CVPs, and definitive
beating hESC-derived cardiomyocytes (hESC-CMs)—after
transplantation into the infarcted rat heart. Furthermore,
we assessed their impact on host cardiac remodeling and
cardiac function.RESULTS
Cardiovascular progenitor (hESC-CVP; day 5 of differentia-
tion) and definitive cardiomyocyte (hESC-CM; beating cells
at approximately day 15 of differentiation) preparations
were obtained by directing differentiation of H7 hESCs to-
ward the cardiovascular lineage. Briefly, cells were allowed
to form embryoid bodies in the presence of defined serum-
free medium as previously described (Yang et al., 2008).
Mesoderm induction was accomplished using bone
morphogenetic protein 4 (BMP4), activin A, and basic fibro-
blast growth factor (BFGF) (Figure S1). On day 5 of differen-
tiation (at the time of the injection procedure), hESC-CVP
preparations contained 74% ± 4% tripotential cardiovascu-
lar progenitor (from 57% to 92%, identified by flow cytom-
etry based on expression of KDR and PDGFRa; Figure 1B)
(Yang et al., 2008). Over time in culture, these mesodermal
progenitors gave rise to a cell population that contained pre-
dominantly cardiomyocytes (70%± 11%; from54% to 91%;
cTNT by flow cytometry at day 14) with a small percentage
of endothelial cells (1.6% ± 0.1%) and smooth muscle cells
(6.5% ± 3.5%), as assessed by flow cytometry for human
CD31+ and SMA+/cTNT cells, respectively (Figure 1C).
Fresh hBM-MNC preparations were harvested from the
posterior iliac crests of healthy donors. Flow cytometry per-
formed on each preparation at the time of injection (Table
S3) demonstrated that 73% ± 4% expressed the common
leukocyte antigenCD45, 11% ± 2% expressed the erythroid
marker glycophorin A, and 5% ± 1% expressed the progen-
itor marker c-KIT. As expected, the hBM-MNCs were nega-
tive for cardiomyocytemarkers (Figure 1D) and contained a
low percentage of endothelial cells (1.1% ± 0.4%; CD31+).
Colony-forming assays in methylcellulose confirmed
viability and normal functional properties of the bone
marrow product (Figure 1F). These features demonstrate
that our hBM-MNC preparations were healthy and repre-
sentative of normal unfractionated bone marrow.754 Stem Cell Reports j Vol. 5 j 753–762 j November 10, 2015 j ª2015 TheTo determine the physiologic consequences of cell trans-
plantation, we compared the functional outcome following
transplantation of these cells to that observed with
control hearts receiving non-cardiac hESCneuroectodermal
derivatives (a cell population that has been shown not to
affect heart function or remodeling after myocardial infarc-
tion; Fernandes et al., 2010; Laflamme et al., 2007; Shiba
et al., 2012). Non-cardiac derivatives of hESCs (Non-Cardio)
were obtained as previously described, using a monolayer
derivation protocol without exogenous growth factors
(Chong et al., 2014; Fernandes et al., 2010; Laflamme
et al., 2007) performed in parallel of the hESC-CVP/hESC-
CM differentiation protocol (Figure S1). Those preparations
contained virtually no cardiomyocytes (0.3% ± 0.2%
by flow cytometry) or endothelial cells (0.1% ± 0.1%)
(Figure 1E).
The impact of transplanting these four cell populations
was assessed in an athymic rat model of myocardial infarc-
tion, induced by 60 min of ischemia followed by reperfu-
sion (Figure 1A). Myocardial infarction was confirmed
by echocardiography on the day of cell transplantation
(4 days after the ischemia-reperfusion procedure). To
ensure comparability among groups, we excluded from
the study animals with baseline fractional shortening
>40% or that subsequently demonstrated no histologically
identifiable infarct. After randomization, rats underwent
intra-myocardial injection of either 103 106 cardiovascular
progenitor (hESC-CVP; n = 9), definitive cardiomyocytes
(hESC-CMs; n = 11), hBM-MNCs (n = 11), or non-cardiac
derivatives of hESCs (n = 13). Mortality after cell transplan-
tation is given in Table 1 and ranged from 9% in the hBM-
MNC group to 27% in the hESC-CM group.
All physiological studies were conducted and interpreted
by investigators blinded to the animal’s treatment. Echo-
cardiography (Figure 2A) performed just before transplanta-
tion (4 days after ischemia/reperfusion [I/R]) demonstrated
that, at this early time point, rats already showed signs of
negative remodeling with ventricular dilation and reduced
contractile function (Figures 2A and 2C). In a separate
cohort of uninjured rats, fractional shortening (FS) aver-
aged 51.0% ± 2.1%, whereas in our infarcted groups, FS
ranged from 28.9% ± 1.1% to 31.8% ± 0.8%. Importantly,
the pre-transplantation left ventricular dimension (left
ventricular end diastolic and end systolic dimension;
LVEDD and LVESD, respectively) and FS were similar in
all groups (Figure 2C), indicating effective randomization
and comparable infarct sizes among the animals.
By 28 days after cell transplantation (32 days post-
myocardial infarction), animals that received the non-car-
diac cell control population showed significant ventricu-
lar dilation (+18%, p < 0.001, and +26%, p < 0.001, for
LVEDD and LVESD, respectively) and decreased fractional




Figure 1. Study Design and Analysis of
Cell Preparations
(A) Nude rats were subjected to 60 min
ischemia followed by reperfusion. At 4 days
after injury, animals underwent a repeat
thoracotomy and intra-myocardial injection
of either hESC-CVP, hESC-CM, hBM MNC, or
non-cardiac derivatives of hESCs in a pro-
survival cocktail. To ensure xenograft sur-
vival, we treated all animals from days1 to
day +7 post-transplantation with cyclo-
sporine A. Endpoints included echocardiog-
raphy and measurement of blood flow with
microspheres (both performed at days 0 and
28 post-transplantation), and histology (on
day +28 post-transplantation).
(B–F) Human cell preparations were char-
acterized by flow cytometry on the day of
cell injection. At day 5 after commencement
of differentiation, the cardiovascular pro-
genitor population (hESC-CVP preparation)
was characterized using the anti-human KDR
and anti-human PDGFRa antibody in (B). At
day 14 after commencement of differentia-
tion, hESC-CVPs have matured into hESC-
CMs, and the percentage of cardiomyocytes,
endothelial cell, and smooth muscle cell was
evaluated by cTNT/alpha-SMA co-staining
and hCD31 immunostaining (C). In BM-MNC
and non-cardiac preparations (D and E), the
percentage of cardiomyocytes, endothelial
cell, and smooth muscle cell was evaluated
similarly. Further characterization of BM-
MNCs is provided in Table S3. Representative
photomicrographs of colonies obtained from
a colony-forming unit assay performed on a
BM-MNC are shown in (F). BFU-E, red blood
cell colonies known as Burst forming unit;
CFU-GM, myeloid cell colony; CFU-MIX,
mixture of cell types from one multipotent
progenitor. Scale bars represent 200 mm for
CFU-GM and BFU-E and 50 mm for CFU-MIX.measurement at 4 days post-infarction (Figures 2B and
2C). Similarly, left ventricular dimension increased in
the hBM-MNC group (+10%, p < 0.005, and +15%, p <
0.05, for LVEDD and LVESD, respectively); however, this
group did not demonstrate a significant decline in global
systolic function (+0.5% of FS between days 4 and 28;
p = NS). In striking contrast, there was no dilation of the
left ventricle at end-systole or end-diastole in hESC-CM-
and hESC-CVP-injected groups, and the FS improved
significantly (+16% and +28% when compared to base-
line; p < 0.001 and p < 0.05, respectively). There were no
differences between the hESC-CM and hESC-CVP groups
in terms of ventricular dimension or FS, indicatingStem Cell Requal potency for restoration of cardiac structure and
function.
At 28 days post-transplantation, animals were eutha-
nized, and their hearts were harvested to assess the size,
phenotype, and distribution of the graft, as well as the
extent of the scar. All animals showed scar formation and
thinning of the involved left ventricular free wall at
32 days after ischemia-reperfusion (Figure 3A). The hESC-
CVP, hESC-CM, and hBM-MNC groups showed a trend to-
ward smaller scar sizes compared with the non-cardiac
group, but this did not achieve statistical significance
(10% ± 3.1%, 9.7% ± 1.2%, 9.7% ± 1.5%, and 14.1% ±
2.8% of the left ventricle for the hESC-CVP, hESC-CM,eports j Vol. 5 j 753–762 j November 10, 2015 j ª2015 The Authors 755








Quality Control of the Cell
Preparation Was Not Met
Animals Included
in the Study Mortality
hESC-CVPs 14 2 0 4 8 2/14 (14%)
hESC-CMs 15 4 0 0 11 4/15 (27%)
BM-MNCs 12 0 1 0 11 1/11 (9%)
Non-cardiac 16 2 1 0 13 3/16 (19%)hBM-MNC, or Non-Cardiac group, respectively) (Figure 3B).
All hESC-CM and hESC-CVP recipient hearts contained
islands of human cardiac grafts encapsulated by scar tissue
within the left ventricular free wall (Figure 3C). In contrast,
surviving human cells were found in only 3 of 11 recipients
of non-cardiac derivatives at 28 days post-transplantation.
Those human grafts were very small (<0.001% of the left
ventricle) and did not contain any cardiomyocytes (nega-
tive b-MHC immunostaining) but consisted primarily of
epithelial cells (Figure S3). Similar to previous reports (Lof-
fredo et al., 2011),wedidnot observe any long-term survival
of human-derived cells inhBM-MNC recipients using in situ
hybridization to detect human pan-centromeric sequences.
In hESC-CVP and hESC-CM recipients, human grafts
were predominantly located within the central regions of
the scar. However, small myocardial implants in the peri-
infarct (border) zone or within the non-infarcted host tis-
sue were also found. The human origin of the graft was
confirmed by in situ hybridization with a human pan-
centromeric probe (hPCP; Figures 3C and 3D). Graft size
tended to be larger in the hESC-CM recipients versus the
hESC-CVP recipients (2.1% ± 0.5% versus 1.2% ± 0.5% of
the LV; 17% ± 3% versus 10% ± 6% of the scar; Figure 3E),
but this did not achieve statistical significance. Rare micro-
scopic aggregates of epithelial cells were observed in 2 of 9
hESC-CVP and 4 of 11 the hESC-CM recipients, but careful
examination of the histology confirmed absence of tera-
tomas (see Figure S3). In both groups, human grafts were
composed mainly of cardiomyocytes expressing myosin
heavy chain, cardiac troponin cTNTandNKX2.5, andmyo-
fibrils with readily identifiable sarcomeres (Figures 3D and
3F). In larger human grafts, we occasionally observed a
core composed of non-human-derived cells. Those host-
derived cells had a fibroblastic morphology and were nega-
tive for endothelial, epithelial, and contractile markers
(RECA, pan cytokeratin, and MF20, respectively), and sur-
rounding tissue was rich in collagen (picrosirius red stain-
ing; Figure 3C). These void spaces may represent remnants
of necrotic cores from cell injection.
To further assess how cell transplantation affected the
host tissue, we evaluated the vascularization of themyocar-
dium. Using intraventricular infusion of neutron-activated756 Stem Cell Reports j Vol. 5 j 753–762 j November 10, 2015 j ª2015 Themicrospheres at two different time point of the study (at
the time of cell injection and at the time of sacrifice), we
did not observe evidence of enhanced blood flow in any
group at any time. Evaluation of human-derived endothe-
lial cells (by hCD31 immunostaining; Figure 4A) in the
hESC-CVP and hESC-CM groups showed rare presence of
vessel-like lumens in 1 of 9 and 4 of 11 animals, respec-
tively (fewer than ten cells per animal). However, staining
for rat endothelium with RECA confirmed the widespread
presence of host-derived vascularization within hESC-CM
and hESC-CVP grafts (Figure 4B). We did not observe any
vascular density difference between those two groups (Fig-
ure 4C). In both cases, vascular lumen density within the
human graft was lower than within the surrounding host
myocardium (Figure 4B). Similarly, vascular density within
the graft-free scar tissue was not significantly different be-
tween the four cell-injected groups, suggesting that cell in-
jection or cardiac muscle formation has little effect on the
revascularization of the scar (Figure 4D). In contrast, evalu-
ation of the vascular density in myocardial areas remote
from the infarcted zone revealed higher lumen density in
the hBM-MNC-injected group when compared with the
hESC-CVP or the non-cardiac group (Figure 4E). However,
we did not observe any significant difference between the
hESC-CM, hESC-CVP, and non-cardiac groups, suggesting
little effect of human cardiac grafts on angiogenesis.DISCUSSION
In the present study, we demonstrated that hESC-CVPs can
engraft without tumor formation and have a beneficial ef-
fect on the negative remodeling of the heart, in an extent
similar to fully differentiated cardiomyocytes (hESC-CMs).
Then, using a side-by-side comparison, with blinded anal-
ysis,we showed thatwhile hBM-MNCs canhalt the negative
remodeling of the infarcted heart both hESC-CVPs and
hESC-CMs had greater beneficial effects than hBM-MNC
transplantation on the contractile function of the heart.
Improvement of cardiac function after transplantation
of various types of cells has been extensively shown in
different animal models and species. However, because ofAuthors
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Figure 2. Cardiac Function after Cell
Injection
Evaluation was performed showing the effects
of cell transplantation on post-infarct ven-
tricular function by echocardiography at
28 days after cell injection.
(A) Representative short axis of M-mode im-
ages of hearts of hESC-CVP, hESC-CM, BM-MNC,
and non-cardiac recipients at baseline and at
the 1-month time point. There was reduced
ventricular dilation and increased contrac-
tility in the hESC-CM and hESC-CVP recipients
compared with non-cardiac or BM-MNC re-
cipients. Scale bar represents 1 cm.
(B) Individual assessments of the infarcted
rats before (baseline) and 1 month after cell
injection show a global increase of fractional
shortening (FS) in hESC-CVP- and hES-CM-in-
jected animals. Fractional shortening remained
steady in BM-MNC-injected hearts and signifi-
cantly decreased in the non-cardiac recipients.
(C) Transplantation of hESC-CMs or hESC-CVPs
was associated with a decrease in LVEDD and a
steady LVESD, resulting in a significant in-
crease in fractional shortening at 4 weeks. In
contrast, LVEDD and LVESD increased in both
BM-MNC and non-cardiac recipients, and frac-
tional shortening decreased significantly in
the non-cardiac recipients (hESC-CVP, n = 8;
hESC-CM, n = 11; BM-MNC, n = 11; and non-
cardiac recipients, n = 13).the different models, cell processing procedures, delivery,
and varying endpoints, comparison of different cell sources
is difficult. In fact, direct comparison has been addressed in
only a few studies. When transplanted in a rabbit infarct
model, both dermal fibroblast and skeletal myoblasts
improved cardiac compliance, but onlymyoblasts improved
systolic function (Hutcheson et al., 2000). In a rat model,
both skeletal myoblasts and fetal cardiomyocytes showed
heart function improvement to the same extent (Scorsin
et al., 2000). In three other studies, cardiomyocytes and skel-
etal myoblast were both compared with marrow-derived
cells. In both cases, their transplantation in a myocardial
injury model improved cardiac function to a similar degree
as bonemarrow-derived cells (Paulis et al., 2013; Thompson
et al., 2003; Yau et al., 2003). Although these studies indicate
that implanting multiple cell types improves function, not
every cell type is suitable for clinical use.
Our study compared human BM-MNCs (the cell type has
beenwidelyused in clinical trials)with twohESCderivatives.Stem Cell RThis cardiac cell therapy was studied to compare the efficacy
of two cardiovascular derivatives of hESCs with a cell type
currently in clinical trials (humanBM-MNCs). By comparing
to control non-cardiac derivatives of hESCs (a cell source
proven to have no effect on cardiac function after transplan-
tation) (Laflamme et al., 2007; Shiba et al., 2012; van Laake
et al., 2007), we confirmed that hBM-MNCs do have a
modest but significant beneficial effect on cardiac contractile
function. Aswas previously showed inpreclinical studies, we
did not observe any cell survival 1 month after the injection
of BM-MNCs (Kocher et al., 2001; Paulis et al., 2013; van der
Bogt et al., 2008). Taken together, those results prove that the
preservation of cardiac function by hBM-MNC transplanta-
tion is not attributable to transdifferentiation of the injected
cells into cardiomyocytes. Rather, benefit appears to be
attributable to an augmentation of vascularization in the
area remote from the infarct, confirming the paracrine hy-
pothesis of such therapeutic strategy. Interestingly, using





Figure 3. Histological Evaluation of
Human Grafts at 1 Month after Trans-
plantation
(A) Representative picrosirius red/fast
green-stained histological sections from
recipients of hESC-CVP, hESC-CM, hBM-
MNC, and non-cardiac hESC derivatives at
day 28 after cell transplantation. Note that
all animals showed the presence of scar
tissue (red) within the left ventricular
segment. Scale bar represents 2 mm.
(B) Infarct size expressed as a percentage
of left ventricular area was not significantly
different among the four groups (hESC-CVP,
n = 4; hESC-CM, n = 10; hBM-MNC, n = 10;
and non-cardiac hESC-derivatives, n = 4).
(C) Serial sections of a hESC-CM graft
stained with fast green/picrosirius red
(left) and detected by in situ hybridization
using hPCP (right).
(D) Detail of region within black box from
(C) showing the grafts contained numerous
human cells (hPCP), rich in cardiomyocytes
(sarcomeric MHC and bMHC), and devoid of
epithelial elements (cytokeratin, CYTOK).
(E) Human graft size was not significantly
different between the hESC-CVP and hESC-CM
recipients (n = 4 and n = 10, respectively).
(F) Confocal imaging of the human graft
(human NKX2.5 pink), demonstrating pres-
ence of contractile apparatus (Troponin T;
green).did not observe any significant difference in blood flow
among any of our groups. One explanation could be that
an angiogenic response is occurring at the post-capillary
level, downstream of the main resistance vessels that deter-
mine overall blood flow (Figure S2C). This would imply
that blood flow in these neovessels is limited compared
with theuninjured circulation andmaynot provide substan-
tial nutrient value. Interventions that induce hierarchical re-
modeling of the upstream vessels (arteriogenesis) would be
expected to have greater impact on flow than those that
only grow new capillaries. Although in our study injection
of hESC-CVPs or hESC-CMs did not increase cardiac vascu-
larization when compared with our non-cardiac cell control
group, we cannot infer a total absence of angiogenic effect,
since injection of non-cardiac derivatives could possibly
favor angiogenesis. Inclusion of a vehicle only or no injec-
tion control group would be necessary to confirm the
absence of neovascularization.
One hypothesis leading into this study was that hESC-
CVPs would be superior to hESC-CMs by giving larger,
morewidely distributed grafts that contained human cardi-758 Stem Cell Reports j Vol. 5 j 753–762 j November 10, 2015 j ª2015 Theomyocytes and human vessels. This hypothesis was not
supported by the data. Instead, the hESC-CVP grafts tended
to be smaller than the hESC-CM grafts, and neither group
showed significant numbers of human vessels. It is possible
that the hESC-CVP group could be further improved, e.g.,
by co-delivering factors that promote endothelial differen-
tiation, expansion, and survival, but it seems clear that host
factors alone do not support infarct vascularization from
these cells.
An interesting finding of our present study is that hESC-
CMs not only blocked adverse dilation, as previously
observed, but also led to improved fractional shortening.
This improvement in contractility was not observed in
our previous studies with the same animal model (La-
flamme et al., 2007). One factor that could explain the
additional beneficial effect is use of a different cell differen-
tiation protocol, leading to a cell therapy product that con-
tains not only cardiomyocytes but also endothelial cells
and smooth muscle cells (whereas in the previous cell dif-
ferentiation protocol, smooth muscle and endothelial cells
were absent from the final product; Laflamme et al., 2007;Authors
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Figure 4. Evaluation of Revascularization at
1 Month after Cell Injection
(A) Human specific CD31 immunostaining
showing rare human-derived vessels within the
graft.
(B) Rat endothelial cell (RECA) immunostain-
ing of heart injected with hESC-CVPs showing
capillary density within the graft is sparse
when compared with the adjacent host tissue.
(C) Vascularization of the human graft is
similar in hESC-CM and hESC-CVP recipients (as
human grafts were absent from the non-car-
diac and hBM-MNC groups, graft vasculariza-
tion could not be evaluated in those groups).
(D and E) Scar vascularization did not differ
between groups (D). However, in the area
remote from the scar zones (E), we observed
enhanced vascularization in the hBM-MNC
group.
(C–E) hESC-CVP, n = 4; hESC-CM, n = 10; hBM-
MNC, n = 10; and non-cardiac hESC derivatives,
n = 4.Fernandes et al., 2010). This suggests that cell types other
than cardiomyocytes are essential in the beneficial effect
of cardiac cell therapy. This beneficial effect can be medi-
ated by the secretion of paracrine factors or by facilitating
the delivery of paracrine factor through neoangiogenesis.
Another potential difference is the use of a modified pro-
survival cocktail in the current study. In any case, FS of
the hESC-CVP and hESC-CM group reach only 35% and
37%, significantly below that of the normal nude rat
(51% ± 2%; n = 9, data not shown), indicating that the
function was not completely restored and leaving room
for further improvement.
A major finding of our study is that both hESC-CVPs and
hESC-CMs showed a superior beneficial effect on cardiac
function when compared with hBM-MNCs. This study also
suggests distinct mechanisms of action between the hESC-
derived cardiomyocytes andhBM-MNCcell delivery: remus-
cularization, enhanced vascularization of the host myocar-
dium, or release of paracrine factors. Our group recently
used guinea pig and macaque cardiac injury models to
show that, once injected into the heart, hESC-CMs can
couple and beat in synchrony with the host myocardium
(Chong et al., 2014; Shiba et al., 2012) at rates up to 240
beat perminute.However, wehavenotmeasured electrome-
chanical coupling in this study. Therefore, we cannot
commentontheextent towhich theobservedbenefit results
from new force generating units versus paracrine effects.
There was somewhat greater mortality in the hESC-CMStem Cell Rgroup (27%) compared with the hBM-MNC group (9%),
and we cannot exclude earlier deaths of animals with larger
infarcts. Since after excluding these animals bothgroupshad
comparable pre-treatment cardiac dysfunction, this differ-
ence is unlikely to influence the treatment effect.
Although we attempted to reproduce key clinical ele-
ments such as the use of human cell products and an
ischemia-reperfusion model in the host, a few caveats
should be emphasized in applying these data to humans.
Importantly, our animals did not receive any additional
pharmacological treatment such as beta-adrenergic recep-
tor blockers or angiotensin-converting enzyme inhibitors.
Interestingly, preclinical studies performed with skeletal
myoblasts demonstrated that the benefits of cell transplan-
tation lasted longer than the benefit associated with angio-
tensin-converting enzyme inhibition (Fujii et al., 2003)
and that cells and pharmacological beneficial effects were
additives (Pouzet et al., 2001). This demonstrated that
cell transplantation can augment cardiac function in the
context of standard pharmacological treatment. Another
limitation pertains to the use of a xenotransplantation
model, which precludes learning how adaptive immune re-
sponses would evolve in the setting of allogenic cell ther-
apy in humans. Importantly, our preclinical study assessed
the change in cardiac function only within the first 28 days
after cell transplantation. It is unknown whether the car-
diac functional improvement will be sustained at later
time points. It is noteworthy that hESC-CM delivery in aeports j Vol. 5 j 753–762 j November 10, 2015 j ª2015 The Authors 759
murine model of myocardial infarction similarly demon-
strated cardiac functional improvements at 1 month; how-
ever, this was not sustained on reassessment at 3 months
(van Laake et al., 2007; van Laake et al., 2008). Further
studies would need to be performed to evaluate the long-
term beneficial effect of the hESC-CM protocol used in
the current study. Finally, cells were delivered by direct in-
jection into the infarct region, whereas in clinical trials, the
predominant route of BM-MNC delivery is by intra-coro-
nary injection.
In summary, using direct side-by-side comparison, associ-
atedwith a blinded analysis of cardiac function, we demon-
strated the superiority of hESC cardiac derivatives over
BM-MNC transplantation in improving cardiac function
28 days after transplantation. These data, combined with
our recent report demonstrating that hESC-CM transplan-
tation remuscularizes a substantial fraction of the non-hu-
man primate infarct with synchronously beating human
myocardium (Chong et al., 2014), support continued
research in the use of cardiomyocytes derived from plurip-
otent human stem cells for heart regeneration.EXPERIMENTAL PROCEDURES
Preparation of hESC-Derived Cardiomyocytes
To ensure comparability, we derived the cardiomyocytes, progeni-
tors, and non-cardiac derivative used for this study from the same
batch of human ESC (H7) that was expanded and cryopreserved
until thawing for differentiation.
The expansion phase of undifferentiated hESCs was performed
on mouse embryonic fibroblasts (MEFs) in medium consisting of
DMEM/F12 supplemented with 20% KnockOut serum replace-
ment (Invitrogen), L-glutamine, non-essential amino acids, beta-
mercaptoethanol, and BFGF (10 ng/ml; Peprotech). Cells were
passaged using collagenase IV and trypsin, as well as the ROCK in-
hibitor Y-27632 (Rho-associated kinase inhibitor; 10 mM, Tocris) to
enhance cell survival. Human ESCs were depleted of MEFs by at
least two passages on Matrigel-coated plates before cryopreserva-
tion. For growth onMatrigel, cells were maintained in MEF-condi-
tioned medium (MEF-CM) supplemented with 8-ng/ml BFGF.
Cardiac differentiation was induced using an embryoid body
method previously described (Yang et al., 2008). For embryoid
body formation, cells were resuspended into low-attachment plates
in StemPro-34 medium (Invitrogen) supplemented with L-gluta-
mine (15 mg/ml), ascorbic acid (50 mg/ml), transferrin (150 mg/ml),
andmonothioglycerol (50 mg/ml). For further directionof cell differ-
entiation toward the cardiovascular lineage, the basal media was
supplemented with 0.5 ng/ml bone morphogenic protein 4
(BMP4, R&D) for 24hr followed by 10ng/ml BMP4, 6 ng/mlActivin
A (R+D), and 5 ng/ml BFGF for 3 days. On day 4 of differentiation,
the embryoid bodies were dissociated into single cells using trypsin
and seeded ontoMatrigel-coated plates at a density of 105 cells/cm2
inStemPro.Mediumwaschangedevery3–4days thereafteruntil day
14 of differentiation. For non-cardiac preparations (principally neu-
roectoderm), we used the same batch of hESCs (H7), but differentia-760 Stem Cell Reports j Vol. 5 j 753–762 j November 10, 2015 j ª2015 Thetion was performed under monolayer condition, as previously
described (Fernandes et al., 2010; Laflamme et al., 2007).
Cell Preparation before Injection
At 1 day prior injection, hESC derivatives (progenitors and defini-
tive and non-cardiac derivatives) were subjected to a pro-survival
protocol, modified from that previously shown to enhance
engraftment post-transplantation (Fernandes et al., 2010; La-
flamme et al., 2007). In brief, at days 4 or 14 of differentiation
for hESC-CVPs or hESC-CMs, respectively, cultures were heat
shocked with a 30-min exposure to 43C media, followed by a re-
turn at 37C in fresh media supplemented with cyclosporine A (to
close themitochondrial transitionpore; 0.2 mM, Sandimmune,No-
vartis). One day later, cultures underwent a 1-hr pretreatment with
Y-27632 (Rho-associated kinase inhibitor; 10 mM) and then were
harvested with 0.25% trypsin/0.5mMEDTA (Invitrogen). After be-
ing washed with DMEM/F12 supplemented with DNase (Invitro-
gen, 100 U/ml), 10 3 106 cells were suspended in a 100 ml-volume
per animal. The injection vehicle consisted of growth factor-
reduced Matrigel in basal StemPro-34 medium (50% vol/vol), sup-
plemented with L-glutamine, ascorbic acid, transferrin,monothio-
glycerol, cyclosporine A (200 nM, Wako), and Y-27632 (10 mM).
Fresh bone marrow mononuclear cells were purchased from All-
Cells LLC (ABM024). After overnight shipment, they were washed
twice in DMEM/F12 and resuspended at the same density and in
the same vehicle as hESC derivatives (10 3 106 cells per 100 ml).
For immunophenotyping purpose, aliquots of each cell batch
were preserved for flow cytometry analysis at the time of cell
injection.
Myocardial Infarction Model and Cell
Transplantation
All animal experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Animals published
by the U.S. NIH (NIH Publication No. 85-23, revised 1996) and
were approved by our institutional animal care and use commit-
tee. Themyocardial infarctionmodel and cell transplantation pro-
tocol have been described previously in several reports by our
group (Fernandes et al., 2010; Laflamme et al., 2007). In brief,
myocardial infarction of athymic male Sprague Dawley rats (rnu-
rnu, 200–250 g, Charles Rivers) was induced by 60 min of I/R
injury (ligation of the left anterior descending artery by 7-0 Prolene
suture). Four days after I/R, animals underwent echocardiographic
evaluation, and animals with fractional shortening >40% were
excluded on the basis of small infarcts. Qualified animals were
randomly assigned to one of the four treatment groups (Figure 1).
A total of 10 3 106 cells were injected at three sites within the left
ventricular wall (two injections at the lateral borders of the infarct
and one in the central ischemic zone). All rats received daily sub-
cutaneous injections of cyclosporine A (0.75 mg/day, Wako Pure
Chemicals a sub-immunosuppressive dose that should facilitate
mitochondrial permeability pore closure) starting 1 day before
engraftment and continuing for 7 days after engraftment.
Flow Cytometry
Human ESC-CMs were analyzed by flow cytometry at the cardio-
vascular progenitor stage, definitive stages (days 4 and 14 ofAuthors
differentiation, respectively). For non-cardiac derivative and bone
marrow mononuclear cells, a sample of the cells was kept at the
time of injection. Primary antibodies are detailed in Table S1, and
the flow cytometry analysis was performed using a BD FACSCanto.
Gating parameters were defined using cells incubated with only
the secondary antibody and omitting the primary antibody.
Cardiac Function Evaluation
Cardiac function was evaluated by echocardiography on lightly
anesthetized animals (2% isoflurane; Novaplus). Left ventricular
end-diastolic dimension (LVEDD), end-systolic dimension (LVESD),
and heart rate were measured by transthoracic echocardiography
(GE Vivid 7) with a 10S (10 MHz) pediatric transducer. Fractional
shortening was calculated by this equation: FS = 100 3 (LVEDD –
LVESD)/LVEDD. All cardiac function evaluations (echocardiogra-
phy and their analysis) were performed by an investigator blinded
to the respective treatment.
Neutron-Activated Microspheres and Tissue
Processing
Evolution of cardiac blood flow after cell injection was evaluated
using the neutron-activated microsphere technique (Reinhardt
et al., 2001). Gold and Samarium microspheres (200,000 of 15-
mm diameter in 200 ml; BioPAL) were injected into the left ventric-
ular chamber via a 25G catheter at a controlled rate of 300ml/hr at
the time of cell injection and at the time of sacrifice, respectively.
Microspheres were allowed to circulate for 5 min, and chest was
either closed (at the 4-day time point) or heart was arrested by in-
jection of potassium chloride (at the 1-month time point). At the
time of sacrifice, hearts were harvested, perfused with PBS, and
then paraformaldehyde (4%, 50 ml, 80–100 mmHg pressure).
Hearts were cut into short-axis sections using a rat heart slicer ma-
trix (Zivic Instruments). Four sections per heart were collected
starting at the apex (Figure S2); the remaining heart tissue (closer
to the base) was discarded. At least two sections per heart were at
stored at 4C until further processing for histological analysis.
The two other sections were used for microsphere analysis, and
the infarct and uninjured segment of each section were isolated
under visualization of a dissecting microscope. Infarct and non-
infarcted tissues were weighed and were sent for analysis (BioPAL).
For calculation of relative regional myocardial blood flow, relative
decay per minute of the pooled infarct samples and uninjured
samples was normalized to tissue weight. Blood flow to the infarct
region was expressed as a percentage of that in the non-infarcted
region using the following formula: 1003 (relative decay per min-
ute in infarct region / tissue weight) / (relative decay per minute in
uninjured region / tissue weight).
Histology
Histological studies were performed as previously detailed by our
group (Fernandes et al., 2010; Laflamme et al., 2007). For immuno-
histochemistry, we used the primary antibodies detailed in Table
S2, followed by either fluorescent secondary antibodies (Alexa-con-
jugated, species-specific antibodies from Molecular Probes) or the
avidin-biotin reaction followed by chromogenic detection (ABC
kits from Vector Labs). In situ hybridization against the human-
specific pan-centromeric probe was performed using methods pre-Stem Cell Rviously detailed (Laflamme et al., 2007). For detection, we used
a peroxidase-conjugated anti-digoxigenin antibody (Roche), fol-
lowed by staining with either a chromogenic substrate or fluores-
cent tyramide signal amplification kit (Molecular Probes).Statistical Analysis
All values were expressed as mean ± SEM. Statistical analyses were
performed using Graphpad 4.0 with the threshold for significance
set at level p < 0.05. Echocardiographic outcomeswere analyzed by
ANOVA followed by post hoc comparisons between groups by Tu-
keyHSD. For infarct size and left ventricular thickness, groupswere
compared using a one-way ANOVA followed by a Kruskal Wallis
test. A Student’s t test was used to compare graft size between
hESC-CMs and CVPs.
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